Faron´s financial calendar for 2020

RNS Number : 8985U
Faron Pharmaceuticals Oy
27 November 2019
 

Faron Pharmaceuticals Oy
("Faron" or the "Company")

 

Faron´s financial calendar for 2020

 

Company announcement, 27 November 2019 at 6.00 pm (EET)

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN) ("Faron" or the "Company"), the clinical stage biopharmaceutical company, announces the following dates for the Company's financial reporting in 2020:

 

20 March        Financial Statement release for full year 2019

27 March        Financial Statements for full year 2019

24 September Half-Year Financial Report for the period 1 January - 30 June 2020

 

The Annual General Meeting is planned for 13 May 2020. A separate stock exchange notice will be issued by Faron´s Board of Directors to convene the meeting.

 

For more information please contact:

Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Panmure Gordon (UK) Limited, Nomad and Broker on AIM
Emma Earl, Freddy Crossley
Phone: +44 (0)20 7886 2500

Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen, Jussi Majamaa
Phone: +358 (0)40 555 4727

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
Email:
faron@consilium-comms.com

Distribution
:
Nasdaq Helsinki Ltd
Key media
www.faron.com

About Faron Pharmaceuticals Oy

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Clevegen®, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen® has potential as a single-agent therapy or in combination with other immune checkpoint molecules or other cancer standard cares. Traumakine®, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine®. Faron is based in Turku, Finland. Further information is available at www.faron.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORUBVVRKUAAUAA
UK 100

Latest directors dealings